Statement of Changes in Beneficial Ownership (4)
19 May 2022 - 6:05AM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
MURPHY ANDREW J |
2. Issuer Name and Ticker or Trading Symbol
REGENERON PHARMACEUTICALS, INC.
[
REGN
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) EVP Research |
(Last)
(First)
(Middle)
777 OLD SAW MILL RIVER ROAD |
3. Date of Earliest Transaction
(MM/DD/YYYY)
5/16/2022 |
(Street)
TARRYTOWN, NY 10591
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 5/16/2022 | | M(1) | | 10000 | A | $179.13 | 68470 | D | |
Common Stock | 5/16/2022 | | F(1) | | 6457 | D | $648.31 | 62013 | D | |
Common Stock | 5/17/2022 | | S(1) | | 59 | D | $655.4 | 61954 | D | |
Common Stock | 5/17/2022 | | S(1) | | 58 | D | $656.52 | 61896 | D | |
Common Stock | 5/17/2022 | | S(1) | | 60 | D | $657.51 | 61836 | D | |
Common Stock | 5/17/2022 | | S(1) | | 123 | D | $658.56 | 61713 | D | |
Common Stock | 5/17/2022 | | S(1) | | 77 | D | $660.32 (2) | 61636 | D | |
Common Stock | 5/17/2022 | | S(1) | | 465 | D | $661.46 (3) | 61171 | D | |
Common Stock | 5/17/2022 | | S(1) | | 779 | D | $662.57 (4) | 60392 | D | |
Common Stock | 5/17/2022 | | S(1) | | 472 | D | $663.6 (5) | 59920 | D | |
Common Stock | 5/17/2022 | | S(1) | | 428 | D | $664.32 (6) | 59492 | D | |
Common Stock | 5/17/2022 | | S(1) | | 126 | D | $665.36 | 59366 | D | |
Common Stock | 5/17/2022 | | S(1) | | 352 | D | $666.23 (7) | 59014 | D | |
Common Stock | 5/17/2022 | | S(1) | | 154 | D | $667.49 (8) | 58860 | D | |
Common Stock | 5/17/2022 | | S(1) | | 180 | D | $668.68 (9) | 58680 | D | |
Common Stock | 5/17/2022 | | S(1) | | 153 | D | $669.12 (10) | 58527 | D | |
Common Stock | 5/17/2022 | | S(1) | | 57 | D | $670.49 | 58470 | D | |
Common Stock | | | | | | | | 4285 | I | By 401(k) Plan |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Non-Qualified Stock Option (right to buy) | $179.13 | 5/16/2022 | | M (1) | | | 10000 | (11) | 12/14/2022 | Common Stock | 10000 | $0.0 | 20000 | D | |
Explanation of Responses: |
(1) | Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). |
(2) | Represents volume-weighted average price of sales of 77 shares of Company stock on May 17, 2022 at prices ranging from $660.18 to $660.72. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 17, 2022 at each separate price. |
(3) | Represents volume-weighted average price of sales of 465 shares of Company stock on May 17, 2022 at prices ranging from $661.16 to $661.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 17, 2022 at each separate price. |
(4) | Represents volume-weighted average price of sales of 779 shares of Company stock on May 17, 2022 at prices ranging from $662.29 to $662.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 17, 2022 at each separate price. |
(5) | Represents volume-weighted average price of sales of 472 shares of Company stock on May 17, 2022 at prices ranging from $663.20 to $663.80. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 17, 2022 at each separate price. |
(6) | Represents volume-weighted average price of sales of 428 shares of Company stock on May 17, 2022 at prices ranging from $664.01 to $664.80. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 17, 2022 at each separate price. |
(7) | Represents volume-weighted average price of sales of 352 shares of Company stock on May 17, 2022 at prices ranging from $666.11 to $666.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 17, 2022 at each separate price. |
(8) | Represents volume-weighted average price of sales of 154 shares of Company stock on May 17, 2022 at prices ranging from $667.27 to $667.86. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 17, 2022 at each separate price. |
(9) | Represents volume-weighted average price of sales of 180 shares of Company stock on May 17, 2022 at prices ranging from $668.41 to $668.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 17, 2022 at each separate price. |
(10) | Represents volume-weighted average price of sales of 153 shares of Company stock on May 17, 2022 at prices ranging from $669.00 to $669.21. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 17, 2022 at each separate price. |
(11) | The stock option award vests in four equal annual installments, commencing one year after the date of grant. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
MURPHY ANDREW J 777 OLD SAW MILL RIVER ROAD TARRYTOWN, NY 10591 |
|
| EVP Research |
|
Signatures
|
/s/**Andrew Murphy | | 5/17/2022 |
**Signature of Reporting Person | Date |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. |
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Jul 2023 to Jul 2024